Genomic & theranostic corporate group @biosequence @integragen specializing in precision medicine for the treatment of patients with cancer and genetic diseases
📢 Exciting News! We successfully raised 6.5M euros in Round C financing! Thanks to our shareholders for their confidence in #OncoDNA's vision. Our objective: double-digit, profitable growth in #personalizedmedicine. Introducing the #OncoDEEPKit, empowering tailored solutions!
🚀 Introducing our new lab solutions portal! 🧬🔬 Access cutting-edge scientific info, research papers, clinical trials, and more in oncology, genetics, and precision medicine. 🔗 https://t.co/ZOokKGMobh #labsolutions#oncology#genetics#precisionmedicine#innovation
We are thrilled to unveil the exceptional quality of the OncoDEEP Kit's HRD assessment presented in our new article "Homologous Recombination Deficiency (#HRD) assessment for clinical management using the OncoDEEP Kit" => https://t.co/ZKLIW0YC5A 💥
#labs#precisionmedicine
Our merry team at @OncoDNA is sending their very best wishes for this holiday season🎄and wishing you a sparkling New Year🎉. We are grateful for the trust you have placed in us, and we hope to keep on bringing you closer to your dreams in the year to come✨.
We are delighted to communicate about our collaboration with @LillyPad - Italia to broaden access to biomarker testing for #thyroid cancer patients 🧬.
Discover all details in our press release: https://t.co/oh0Avki5DJ
#oncodna#oncodeep#cancer#precisiononcology#NGS
OncoDNA is pleased to announce a transformational partnership with the Berkshire and Surrey Pathology Services to facilitate Private NGS testing across UK 🙌.
Discover all details in our press release: https://t.co/ypovd0cyTm
#oncodna#oncodeep#precisiononcology
We have launched our new #OncoDEEP Kit during the #ESMO in Paris. It enables laboratories with #NGS capabilities to support oncologists in finding the most effective and personalized treatments for their cancer patients🔬.
Discover all details: https://t.co/f5BoRrVGrD
We have enjoyed attending the annual #ESMO congress, one of the biggest oncology congresses in the world. We look forward to seeing many of you again next year at ESMO in Madrid, Spain, 20-24 October 2023 🙌.
#ESMO#ESMO2022#oncodeepkit#precisiononcology#cancerbiomarkers
ALK. ROS1. FGFR. NTRK. BRAF. They are all #genefusion biomarkers that can predict a patient’s sensitivity to targeted and hormone therapy. Watch the video to understand how to detect them in patients.
https://t.co/zGpOEp7mon
#oncology#OncoDEEP#precisionmedicine
Why test patients with metastatic castration-resistant #prostatecancer for #ARV7?
This #biomarker is associated with a poor prognostic indicator for the efficacy of #hormonetherapies such as abiraterone or enzalutamide.
#OncoDEEP can help detect it =>
https://t.co/ocmkWnzmIA
SYNLAB Group continues to push the boundaries of science, by partnering with @OncoDNA to provide a test that helps to predict which patients will respond positively to certain cancer treatments.
Read more: https://t.co/8RU7pBwSYf
Today, we were happy to welcome MIT REAP - Regional Entrepreneurship Acceleration Program during their tour of the BioPark in Gosselies. We hope this visit has highlighted the potential of Wallonia in terms of innovation and entrepreneurial capacities 🤩.
#oncology#innovation
Why test #NSCLC patients for #METex14 unusual splicing, and #ROS#ALK#RET translocations?
All are associated with FDA-approved #targetedtherapies. Our #OncoDEEP uses #DNAseq#RNAseq to detect such complex biomarkers & flag patients that are eligible.
https://t.co/i4Wgv30vLD
A clinical study highlights the power of combining #NGS and #IHCs to optimize treatment strategies for cancer patients 🧬.
Curious to know more about this study? Access the publication here: https://t.co/i9ecxTghBl
#OncoDEEP#biomarkertest#precisionmedicine#oncology
Our #OncoDEEP technology is transferred to Synlab
laboratories in Germany which will perform comprehensive #biomarker testing of solid tumors and deliver decision support for oncologists. Discover more: https://t.co/FtCFLTiQu0
#oncology#precisionmedicine